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ABSTRACT
Background    The therapeutic effect of chemotherapy 
for liver metastases is currently determined by changes in 
tumor diameter depicted on computed tomography (CT) 
and magnetic resonance imaging, but it cannot accurately 
determine if there is central necrosis. Furthermore, due 
to the risk of radiation exposure and high cost, frequent 
examination using these methods places a heavy burden 
on patients. Meanwhile, real-time observation of blood 
flow and vessel morphology within tumors has become 
possible by contrast-enhanced ultrasonography (CEUS). 
However, use of CEUS in evaluating the therapeutic 
effect of anticancer chemotherapy has rarely been inves-
tigated. This study investigated whether changes in the 
time-intensity curve (TIC) of CEUS are useful indicators 
of the therapeutic effect of chemotherapy.
Methods    Five patients with liver metastases who had 
undergone CEUS before and after chemotherapy were 
included in this study. The TIC of each time point was 
prepared to examine whether the following five TIC 
parameters serve as indicators of the therapeutic effect 
of chemotherapy: peak intensity, time to wash-in, time 
to peak intensity, slope of wash-in, and area under the 
curve. In each parameter, rate of change (ROC) was cal-
culated by the expression [(values before chemotherapy 
minus those after chemotherapy)/those before chemo-
therapy × 100(%)].
Results    (i) Among the five TIC parameters tested, 
ROC of the slope of wash-in and the area under the 
curve reflected the therapeutic effect of chemotherapy 
better than the remaining three parameters. (ii) TIC pa-
rameters after one cycle of chemotherapy were examined 
in two of five patients, and changes in the slope of wash-
in and the area under the curve were in good agreement 
with the computed tomography findings indicative of the 
therapeutic effect after the fourth chemotherapy cycle.
Conclusion    The findings of this study suggest that 
ROC of the slope of wash-in and the area under the 
curve of the TIC are useful in evaluating the therapeutic 
effect of chemotherapy. Furthermore, there is a possibil-
ity that TIC analysis may enable early prediction of the 
therapeutic effect.
Key words    liver; neoplasm metastases; Sonazoid; time 
intensity curve; ultrasonography
The therapeutic effect of chemotherapy for liver me-
tastases is currently determined by changes in tumor 
diameter depicted on computed tomography (CT) and 
magnetic resonance imaging, but it cannot accurately 
determine if there is central necrosis. Frampas et al. 
reported that it was possible to predict the therapeutic 
effect by the change in tumor blood flow using dynamic 
CT.1 However, due to the risk of radiation exposure and 
high cost, frequent examination using these methods 
places a heavy burden on patients.
 Meanwhile, real-time observation of blood flow and 
vessel morphology within tumors has become possible 
by contrast-enhanced ultrasonography (CEUS). Lassau et 
al.2, 3 reported that the time-intensity curve (TIC) param-
eters obtained from CEUS of tumors correlated well with 
the prognosis. Furthermore, Frampas et al.1 reported that 
the area under the curve (AUC), one of the TIC param-
eters, was useful for assessing the blood flow.  However, 
use of CEUS in evaluating the therapeutic effect of anti-
cancer chemotherapy has rarely been investigated. This 
study investigated whether changes in the TIC of CEUS 
are useful indicators of the therapeutic effect of chemo-
therapy. Lassau et al. reported that the TIC parameters 
obtained from CEUS of tumors correlated well with the 
prognosis.2, 3 Furthermore, Frampas et al. reported that 
AUC, one of the TIC parameters, was useful for assess-
ing the blood flow.1 However, use of CEUS in evaluating 
the therapeutic effect of anticancer chemotherapy has 
rarely been investigated. This study investigated whether 
changes in the TIC of CEUS are useful indicators of the 
therapeutic effect of chemotherapy.
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Fig. 1. ROI of the tumor. Circle indicates the ROI. Right image: B-mode. Left image: CEUS-mode. CEUS, contrast-enhanced ultrasonog-
raphy; ROI, region of interest.
SUBJECTS AND METHODS
Five patients with liver metastases from digestive tract 
cancer underwent CEUS before and after chemotherapy 
from February 2011 to February 2015 in Tottori Univer-
sity Hospital and were followed up after chemotherapy. 
The site of the primary tumor was the rectum in two pa-
tients, stomach in two, and esophagus in one. Histologi-
cal types of all primary tumor were adenocarcinoma.
 Ultrasonography was performed using a Aplio XG 
(Toshiba, Tokyo, Japan) and a 3.5 MHz convex probe 
(PVT-375BT). Before CEUS, B-mode ultrasonography 
of the whole tumor was performed to determine the 
slice of images. Then the largest diameter slice of the 
tumor image was selected. A probe was fi xed to obtain 
an image similar to the preselected image, and imaging 
was recorded for 3 min immediately after bolus injec-
tion of Sonazoid (Daiichi Sankyo, Tokyo, Japan) into 
the medial cubital vein. Ultrasound conditions (gain, dy-
namic range, mechanical index, depth, and focus) were 
unaltered throughout imaging of a particular patient. 
CEUS was performed before and after chemotherapy; 
the number of chemotherapy cycles ranged from one to 
fi ve depending on the patient’s condition.
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Fig. 2. TIC parameters. 1) Peak intensity. 2) Time to wash-in. 3) 
Time to peak intensity. 4) Slope of wash-in. 5) Area under the 
curve. TIC, time-intensity curve. dB, decibel.
 ImageLab software ver. 2.9 (Toshiba, Tokyo, Japan) 
was used for image analysis. The region of interest was 
set to surround the entire region of the tumor (Fig. 1).
 A TIC was prepared for each patient for 3 min imme-
diately after Sonazoid injection. Changes in TIC parame-
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ters between before and after chemotherapy were exam-
ined in relation to the CT changes in tumor diameter.
 The following TIC parameters were examined: peak 
intensity, time to wash-in, time to peak intensity, slope 
of wash-in (slope from baseline to peak), and area un-
der the curve (Fig. 2). In each parameter, rate of change 
(ROC) was calculated by the expression, [(values before 
chemotherapy minus those after chemotherapy)/those 
before chemotherapy × 100(%)].
 The therapeutic effect on the tumors was deter-
mined based on the CT changes in tumor diameter in 
accordance with the response evaluation criteria in solid 
tumors (RECIST) complete loss of the target lesion 
(complete response), > 30% decrease in the sum of the 
diameters of the target lesion relative to the baseline 
value (partial response), > 20% increase and 5-mm in-
crease in the sum of the diameters of the target lesion 
relative to the baseline value (progressive disease), and 
small changes that do not meet the above criteria (stable 
disease). 4 
 This study was approved by the Ethics Com-
mittee of the Tottori University Faculty of Medicine 
(1508A020).
RESULTS
The therapeutic effect according to the RECIST was a 
partial response in two patients and progressive disease 
in three (Table 1).
 Figures 3 and 4 show the CEUS images and TIC 
before and after chemotherapy in a patient whose CT 
images indicated a good therapeutic effect (Patient 1, a 
67-year-old woman with primary rectal cancer). 
 CEUS was performed after one cycle and CT was 
performed after four cycles of XELOX therapy (capecit-
abine and oxaliplatin). CEUS images showed weak con-
trast enhancement inside the tumor in the arterial phase 
before chemotherapy and reduced contrast enhancement 
inside the tumor in the arterial phase after chemothera-
py. CT images showed a reduction in tumor size from 57 
to 38 mm (Fig. 3). ROC of  the peak intensity, the slope 
of wash-in and the area under the curve were decreased, 
while that of the time to wash-in and time to peak inten-
sity were increased (Fig. 4). 
 Figures 5 and 6 show the CEUS images and TIC 
before and after chemotherapy in a patient whose CT 
images did not show a therapeutic effect (Patient 3, a 
76-year-old man with primary stomach cancer). 
 CEUS was performed after one cycle and CT was 
Table 1. Patients’ characteristics
Case No. 1 2 3 4 5
Age 67 y 70 y 76 y 80 y 76 y
Sex Female Female Male Male Male
Primary tumor
(Histological type)
Rectum
(Adenoca.)
Rectum
(Adenoca.)
Stomach
(Adenoca.)
Esophagus
(Adenoca.)
Stomach
(Adenoca.)
Evaluation 
of the CT
Time point 4 cycles 3 cycles 4 cycles 7 cycles 5 cycles
Change in tumor diameter 57 mm→38 mm
54 mm
→23 mm
27 mm
→43mm
26 mm
→39 mm
35 mm
→56 mm
Therapeutic effect PR PR PD PD PD
Evaluation 
of the CEUS
Time point 1 cycle 3 cycles 1 cycle 3 cycles 5 cycles
Peak intensity
before  –37.25 –23.16 –35.24 –40.27 –27.24
after  –53.24 –24.40 –36.79 –17.55 –18.45
ROC  –43.9 –5.3 –4.4 56.4 32.2
Time to wash in
before  19 9 17 32 19
after 21 9 18 19 25
ROC 5.3 0.0 5.8 –40.6 31.6
Time to peak 
intensity
before 23 19 38 46 29
after 30 14 22 30 44
ROC 30.4 –26.3 –42.1 –34.8 51.7
Slope of wash-in
before 5.69 4.14 1.18 0.81 1.58
after 0.75 2.21 5.80 2.14 2.18
ROC –86.8 –46.6 391.5 164.2 38.0
Area under the 
curve
before 19.30 17.51 5.65 14.42 22.77
after 1.73 10.03 12.09 23.29 29.31
ROC –91.0 –42.7 114.0 61.5 28.7
Adenoca., adenocarcinoma; after, after chemotherapy; before, before chemotherapy; CEUS, contrast-enhanced ultrasonography; CT, 
computed tomography; No., number; PD, progressive disease; PR, partial response; ROC, rate of change; y, years old.
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Fig. 3. Several images of a case of partial response to chemotherapy. Arrows indicate the tumor. A: CEUS image before chemotherapy. 
Right image: B-mode. Left image: CEUS mode. Weak contrast enhancement was observed inside the tumor in the arterial phase. B: 
CEUS image after chemotherapy. Right image: B-mode. Left image: CEUS mode. Contrast enhancement was reduced inside the tumor in 
the arterial phase. C: CT image before chemotherapy. Right image: Contrast enhanced CT. Left image: Plain CT. The largest tumor was 
57 mm in diameter. D: CT image after chemotherapy. Right image: Contrast enhanced CT. Left image: Plain CT. The largest tumor was 
decreased to 38 mm in diameter. CEUS, contrast-enhanced ultrasonography; CT, computed tomography.
Fig. 4. Graph showing the TIC. Dotted line: TIC before chemo-
therapy. Solid line: TIC after chemotherapy. The peak intensity, 
slope of wash-in, and area under the curve were decreased, while 
the time to wash-in and time to peak identity were unchanged. dB, 
decibel; TIC, time-intensity curve.
performed after four cycles of FP therapy (cisplatin and 
fluorouracil). CEUS images showed contrast enhance-
ment of the tumor margins in the arterial phase before 
chemotherapy and increased contrast enhancement in-
side the tumor in the arterial phase after chemotherapy. 
CT images showed an increase in tumor size from 27 to 
43 mm (Fig. 5). ROC of the time to wash-in, the slope 
of wash-in and the area under the curve were increased, 
while ROC of the peak intensity and the time to peak 
intensity were decreased (Fig. 6). Two patients of case 2 
and 5 underwent CEUS and CT at the same time point 
(3 and 5 cycle). CT images of case 2 patient showed a 
reduction in tumor size, and ROC of the peak intensity, 
the slope of wash-in and the area under the curve were 
decreased based on CEUS fi ndings.  As a patient of case 
5, CT images showed an increase in tumor size, and 
ROC of all parameters of TIC were increased (Table 1).
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Fig. 5. Several images of a case of progressive disease after chemotherapy. Arrows indicate the tumor. A: CEUS image before chemother-
apy. Right image: B-mode. Left image: CEUS mode. Contrast enhancement was observed in the tumor margins in the arterial phase. B: 
CEUS image after chemotherapy. Right image: B-mode. Left image: CEUS mode. Contrast enhancement was observed inside the tumor 
in the arterial phase. C: CT image before chemotherapy. Right image: Contrast enhanced CT. Left image: Plain CT. The largest tumor 
was 27 mm in diameter. D: CT image after chemotherapy. Right image: Contrast enhanced CT. Left image: Plain CT. The largest tumor 
was increased to 43 mm in diameter. CEUS, contrast-enhanced ultrasonography; CT, computed tomography.
Fig. 6. Graph showing the TIC. Dotted line: TIC before chemo-
therapy. Solid line: TIC after chemotherapy. The slope of wash-in 
and area under the curve were increased, while the time to peak 
intensity was decreased; the peak intensity and time to wash-in 
were unchanged. dB, decibel; TIC, time-intensity curve.
 The fi ndings for all fi ve patients are summarized in 
Table 1. ROC of the slope of wash-in and the area under 
the curve, but not in the other TIC parameters, refl ected 
the therapeutic effects based on CT fi ndings.
DISCUSSION
The RECIST, which are based on changes in tumor 
diameter on CT images, are commonly used to eval-
uate the therapeutic effect of chemotherapy for liver 
metastases.5 However, the presence of necrosis in the 
tumor complicates the evaluation, and a more accurate 
approach would be visualization of tumor hemodynam-
ics. CEUS is a highly sensitive and specifi c method for 
detecting liver metastases and provides valuable infor-
mation about tumor hemodynamics and morphology.6–11
 When a tumor grows or shrinks, feeding vessels 
are created or damaged, respectively, and morphologi-
cal changes then become prominent. CEUS reportedly 
allows for visualization of changes in feeding vessels 
before tumor morphology changes, enabling early evalu-
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ation of the therapeutic effect.12–14 This early prediction 
of the therapeutic effect allows alteration of the method 
or schedule of treatment, thereby avoiding unnecessary 
administration of anticancer agents. In this study, we 
performed CEUS prior to CT in three patients and found 
that CEUS was able to know the therapeutic effect of 
anticancer agents at an earlier stage than CT in all cas-
es. Furthermore, this study showed that the findings of 
CEUS performed at the earliest stage of therapy (after 
one cycle) reflected the results of the CT evaluation, sug-
gesting that CEUS may have a possibility to predict the 
therapeutic effect at the earliest stage of chemotherapy. 
Conversely, patients whose CT images indicated a com-
plete response or stable disease were not examined by 
CEUS, and the timing of CEUS and CT examinations 
were not controlled in this study. Further studies with 
more patients and controlled timing of CEUS and CT 
examinations are needed. Additionally, this study ex-
amined liver metastases from digestive tract cancer, but 
the type of primary organ was not controlled because 
there were only five patients included in this study. Liver 
metastases from digestive tract cancer reportedly show 
contrast enhancement in the arterial phase.15 Without 
well-enhanced contrast in the arterial phase, the peak 
intensity, time to wash-in and slope of wash-in cannot be 
accurately calculated. This study indicated that changes 
in the TIC would be useful in the evaluation of the ther-
apeutic effect when contrast enhancement was present in 
the arterial phase. 
 Lassau et al. prepared TICs of CEUS in patients 
with liver metastases from renal cell carcinoma and 
found significant differences in the peak intensity, slope 
of wash-in, time to peak intensity, and area under the 
curve between groups with and without a therapeutic ef-
fect.16 In this study, ROC of the slope of wash-in and the 
area under the curve reflected the therapeutic effect, but 
that of the peak intensity and the time to peak intensity 
showed no relationship with the therapeutic effect. This 
may be explained by differences in the locations of pri-
mary tumors and by the use of angiogenic inhibitors as 
anticancer agents in the previous study. Schirin-Sokhan 
et al. prepared TICs for liver metastases of rectal cancer 
treated with an angiogenic inhibitor and found that in-
creases in the time to peak intensity were observed when 
therapy was effective.14 This suggests that ROC of the 
time to peak intensity might vary depending on the an-
ticancer agents used. Based on the previous and present 
studies, it was thought that the angiogenesis of the tumor 
may reflected the two parameters of TIC (slope of wash 
in and area under curve). Furthermore, Schirin-Sokhan 
et al.14 reported that there were no significant differences 
in the peak intensity, which is in good agreement with 
this study.
 In conclusion, the results of this study indicate that 
in tumors with contrast enhancement in the arterial 
phase, differences in the TIC between before and after 
chemotherapy may serve as useful indicators of thera-
peutic effect for patients with liver metastases. In partic-
ular, ROC of the slope of wash-in and the area under the 
curve appear to specifically reflect the therapeutic effect. 
Furthermore, there is a possibility that TIC analysis may 
enable early prediction of the therapeutic effect.
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